

MAPK9 Antibody (monoclonal) (M02)

Mouse monoclonal antibody raised against a partial recombinant MAPK9. Catalog # AT2793a

Product Information

ApplicationWB, IF, EPrimary AccessionP45984Other AccessionBC032539ReactivityHumanHostmouseClonalitymonoclonalIsotypeIgG1 Lambda

Clone Names 2F8
Calculated MW 48139

Additional Information

Gene ID 5601

Other Names Mitogen-activated protein kinase 9, MAP kinase 9, MAPK 9, JNK-55,

Stress-activated protein kinase 1a, SAPK1a, Stress-activated protein kinase

JNK2, c-Jun N-terminal kinase 2, MAPK9, JNK2, PRKM9, SAPK1A

Target/Specificity MAPK9 (AAH32539, 321 a.a. ~ 424 a.a) partial recombinant protein with GST

tag. MW of the GST tag alone is 26 KDa.

Dilution WB~~1:500~1000 IF~~1:50~200 E~~N/A

Format Clear, colorless solution in phosphate buffered saline, pH 7.2.

Storage Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.

Precautions MAPK9 Antibody (monoclonal) (M02) is for research use only and not for use

in diagnostic or therapeutic procedures.

Background


The protein encoded by this gene is a member of the MAP kinase family. MAP kinases act as an integration point for multiple biochemical signals, and are involved in a wide variety of cellular processes such as proliferation, differentiation, transcription regulation and development. This kinase targets specific transcription factors, and thus mediates immediate-early gene expression in response to various cell stimuli. It is most closely related to MAPK8, both of which are involved in UV radiation induced apoptosis, thought to be related to the cytochrome c-mediated cell death pathway. This gene and MAPK8 are also known as c-Jun N-terminal kinases. This kinase blocks the ubiquitination of tumor suppressor p53, and thus it increases the stability of p53 in nonstressed cells. Studies of this gene's mouse counterpart suggest a key role in T-cell differentiation. Several alternatively spliced transcript variants encoding distinct isoforms have been

reported.


References

Interleukin-1beta induces ICAM-1 expression enhancing leukocyte adhesion in human rheumatoid arthritis synovial fibroblasts: involvement of ERK, JNK, AP-1, and NF-kappaB. Yang CM, et al. J Cell Physiol, 2010 Aug. PMID 20432452.Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. Rose JE, et al. Mol Med, 2010 Jul-Aug. PMID 20379614.The c-Jun NH2-terminal kinase 2 plays a dominant role in human epidermal neoplasia. Ke H, et al. Cancer Res, 2010 Apr 15. PMID 20354187.Polymorphisms in innate immunity genes and patients response to dendritic cell-based HIV immuno-treatment. Segat L, et al. Vaccine, 2010 Mar 2. PMID 20056178.Basal c-Jun NH2-terminal protein kinase activity is essential for survival and proliferation of T-cell acute lymphoblastic leukemia cells. Cui J, et al. Mol Cancer Ther, 2009 Dec. PMID 19996270.


Images



Antibody Reactive Against Recombinant Protein.Western Blot detection against Immunogen (37.07 KDa) .





MAPK9 monoclonal antibody (M02), clone 2F8 Western Blot analysis of MAPK9 expression in HeLa ((Cat # AT2793a)



Immunofluorescence of monoclonal antibody to MAPK9 on HeLa cell. [antibody concentration 10 ug/ml]

Detection limit for recombinant GST tagged MAPK9 is approximately 0.03ng/ml as a capture antibody.





Proximity Ligation Analysis of protein-protein interactions between TRAF2 and MAPK9 HeLa cells were stained with anti-TRAF2 rabbit purified polyclonal 1:1200 and anti-MAPK9 mouse monoclonal antibody 1:50. Each red dot represents the detection of protein-protein interaction complex, and nuclei were counterstained with DAPI (blue).

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.